FI930886A - Foerfarande foer hindrande av avstoetning av transplanterad vaevnad - Google Patents

Foerfarande foer hindrande av avstoetning av transplanterad vaevnad Download PDF

Info

Publication number
FI930886A
FI930886A FI930886A FI930886A FI930886A FI 930886 A FI930886 A FI 930886A FI 930886 A FI930886 A FI 930886A FI 930886 A FI930886 A FI 930886A FI 930886 A FI930886 A FI 930886A
Authority
FI
Finland
Prior art keywords
vaevnad
transplanterad
avstoetning
foerfarande foer
hindrande
Prior art date
Application number
FI930886A
Other languages
English (en)
Other versions
FI104732B (fi
FI930886A0 (fi
Inventor
Denise Faustman
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of FI930886A0 publication Critical patent/FI930886A0/fi
Publication of FI930886A publication Critical patent/FI930886A/fi
Application granted granted Critical
Publication of FI104732B publication Critical patent/FI104732B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
FI930886A 1990-08-30 1993-02-26 Menetelmä transplantaatiossa käyttökelpoisen solun tai kudoksen valmistamiseksi FI104732B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US57515090A 1990-08-30 1990-08-30
US57515090 1990-08-30
US07/671,517 US5283058A (en) 1990-08-30 1991-03-19 Methods for inhibiting rejection of transplanted tissue
US67151791 1991-03-19
US9106105 1991-08-27
PCT/US1991/006105 WO1992004033A1 (en) 1990-08-30 1991-08-27 Methods for inhibiting rejection of transplanted tissue

Publications (3)

Publication Number Publication Date
FI930886A0 FI930886A0 (fi) 1993-02-26
FI930886A true FI930886A (fi) 1993-03-31
FI104732B FI104732B (fi) 2000-03-31

Family

ID=27076606

Family Applications (1)

Application Number Title Priority Date Filing Date
FI930886A FI104732B (fi) 1990-08-30 1993-02-26 Menetelmä transplantaatiossa käyttökelpoisen solun tai kudoksen valmistamiseksi

Country Status (7)

Country Link
US (3) US5283058A (fi)
EP (2) EP0550482A4 (fi)
JP (2) JPH06503810A (fi)
AU (1) AU656150B2 (fi)
CA (1) CA2090009C (fi)
FI (1) FI104732B (fi)
WO (1) WO1992004033A1 (fi)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159751A (en) * 1990-10-25 2000-12-12 The Trustees Of Columbia University In The City Of New York Development of DNA probes and immunological reagents of human tumor associated antigens
DE69231250T2 (de) * 1991-10-21 2001-03-15 Cell Genesys Inc Kombinierte zelluläre und immunsuppressive therapien
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
US5730979A (en) * 1993-03-05 1998-03-24 Universite Catholique Delouvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
US5951983A (en) * 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US7592006B1 (en) * 1993-03-05 2009-09-22 Université Catholique de Louvain Composition comprising the LO-CD2a antibody
US5877396A (en) * 1993-04-23 1999-03-02 Sloan Kettering Institute For Cancer Research Mice mutant for functional Fc receptors and method of treating autoimmune diseases
WO1994028897A2 (en) * 1993-06-07 1994-12-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of an mhc class i suppressor drug for the treatment of autoimmune diseases and transplantation rejection
US20040067157A1 (en) * 1993-07-22 2004-04-08 Clearant, Inc. Methods for sterilizing biological materials
US5679340A (en) * 1994-03-31 1997-10-21 Diacrin, Inc. Cells with multiple altered epitopes on a surface antigen for use in transplantation
EP0751987A1 (en) * 1994-03-31 1997-01-08 Diacrin, Inc. Genetically modified cells for use in transplantation
WO1995026740A1 (en) * 1994-03-31 1995-10-12 Diacrin, Inc. Improved methods for transplantation using modified cells and t cell inhibitory agents
US8715645B2 (en) * 1994-05-27 2014-05-06 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
US5759536A (en) * 1994-05-27 1998-06-02 University Technology Corporation Use of fas ligand to supress T-lymphocyte-mediated immune responses
WO1995034202A1 (en) * 1994-06-15 1995-12-21 Alexion Pharmaceuticals, Inc. Methods for reducing hyperacute rejection of xenografts
US5629194A (en) * 1994-10-21 1997-05-13 Diacrin, Inc. Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity
US6277372B1 (en) * 1994-11-08 2001-08-21 Diacrin, Inc. Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases
US6204053B1 (en) * 1994-11-08 2001-03-20 Diacrin, Inc. Porcine cortical cells and their use in treatment of neurological deficits due to neurodegenerative diseases
US6294383B1 (en) 1994-11-08 2001-09-25 The Mclean Hospital Corporation Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases
WO1996031229A1 (en) * 1995-04-05 1996-10-10 Beth Israel Hospital Association Inhibiting rejection of a graft
CA2217131A1 (en) * 1995-04-20 1996-12-05 Diacrin, Incorporated Modified cells and methods for inhibiting xenograft rejection
EP0827409A1 (en) * 1995-05-15 1998-03-11 Cedars-Sinai Medical Center Compositions and methods for inhibiting xenograft rejection
WO1996037602A1 (en) * 1995-05-26 1996-11-28 Diacrin, Inc. Porcine hepatocytes for use in treatment of disorders characterized by insufficient liver function
US5919449A (en) 1995-05-30 1999-07-06 Diacrin, Inc. Porcine cardiomyocytes and their use in treatment of insufficient cardiac function
AU726441B2 (en) * 1995-08-21 2000-11-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of assessing MHC class I expression and proteins capable of modulating class I expression
US5792604A (en) * 1996-03-12 1998-08-11 University Of British Columbia Method of identifying MHC-class I restricted antigens endogenously processed by cellular secretory pathway
EP0910394A4 (en) * 1996-04-10 1999-09-08 Diacrin Inc PROCESS FOR THE PRODUCTION OF PIG TISSUES WITHOUT PATHOGENS AND SUITABLE FOR TRANSPLANTATION IN MAN
EP0952848A2 (de) * 1996-12-23 1999-11-03 Hilmar Lemke Anti-allergene zusammensetzung
US6849258B1 (en) 1997-07-18 2005-02-01 Universite Catholique De Louvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
US6521448B1 (en) 1997-08-19 2003-02-18 Diacrin, Inc. Porcine MHC class I genes and uses thereof
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
EP1115425B1 (en) * 1998-08-26 2007-03-21 The Regents of the University of California Autoantibody inhibitors
US6365616B1 (en) 1998-08-31 2002-04-02 Sentron Medical, Inc. Methimazole derivatives and tautomeric cyclic thiones to treat autoimmune diseases
US6444205B2 (en) 1998-09-30 2002-09-03 Diacrin, Inc. Transplantation of neural cells for the treatment of chronic pain or spasticity
US6787154B2 (en) * 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
AU774442B2 (en) 1998-10-20 2004-06-24 Salvatore Albani Methods for isolation, quantification, characterization and modulation of antigen-specific T cells
US7485293B1 (en) 1999-02-18 2009-02-03 Faustman Denise L Method for inhibiting transplant rejection
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US6303355B1 (en) 1999-03-22 2001-10-16 Duke University Method of culturing, cryopreserving and encapsulating pancreatic islet cells
US6365385B1 (en) 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
US6878543B1 (en) 1999-10-25 2005-04-12 Nsgene Sa Cultures of GFAP+ nestin+ cells that differentiate to neurons
SI1458853T1 (sl) 2002-05-16 2010-04-30 Absorber Ab Postopki donorsko specifiŽŤnega navzkriĹľnega ujemanja
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7582313B2 (en) * 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
WO2004045376A2 (en) * 2002-11-15 2004-06-03 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
CA2553303C (en) 2004-01-14 2014-06-10 Novahep Ab Human hepatic progenitor cells and methods of use thereof
WO2006074478A1 (en) * 2005-01-10 2006-07-13 Teva Pharmaceuticals Usa, Inc. Substantially pure tolterodine tartrate and process for preparing thereof
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
KR20100014290A (ko) 2006-11-30 2010-02-10 더 유니버시티 오브 브리티쉬 콜럼비아 분자 아주반트로서 ｔａｐ―１ 및/또는 ｔａｐ―２를 포함하는 폭스비리대 치료
EP3400800A1 (en) 2007-01-16 2018-11-14 University Of Rochester Non-human animals with human-glial chimeric brains
CN103458935B (zh) 2010-09-01 2016-08-03 明尼苏达大学董事会 使组织或器官再细胞化以提高其可移植性的方法
US9677042B2 (en) 2010-10-08 2017-06-13 Terumo Bct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
JP6746313B2 (ja) 2012-08-01 2020-08-26 ユナイテッド セラピューティクス コーポレイション プロスタサイクリン処理された内皮前駆細胞による肺動脈性高血圧症の処置
CN111803523A (zh) 2012-08-01 2020-10-23 联合治疗公司 利用间充质干细胞的肺动脉高血压的治疗
EP2943069B1 (en) 2013-01-09 2018-08-15 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
DK2953634T3 (da) 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
MX2016004616A (es) 2013-10-09 2017-01-16 Us Gov Veterans Affairs Parches de células musculares y usos de los mismos.
EP3068867B1 (en) 2013-11-16 2018-04-18 Terumo BCT, Inc. Expanding cells in a bioreactor
JP6783143B2 (ja) 2014-03-25 2020-11-11 テルモ ビーシーティー、インコーポレーテッド 培地の受動的補充
US10779519B2 (en) 2014-05-13 2020-09-22 University Of Rochester Human glial chimeric model for drug candidate assessment in human gliotrophic viral infections and progressive multifocal encephalopathy
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
JP2018512172A (ja) 2015-03-26 2018-05-17 ミロマトリックス メディカル インコーポレイテッド ガス充填された脱細胞化細胞外マトリックス
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
DK3447075T3 (da) 2015-05-15 2023-11-13 Massachusetts Gen Hospital Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EP3355914B1 (en) 2015-09-29 2024-03-06 The General Hospital Corporation A composition comprising bcg for reducing cholesterol.
CN109476745B (zh) 2016-05-13 2023-11-24 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
ES2927406T3 (es) 2016-10-24 2022-11-04 United Therapeutics Corp Potenciación de las propiedades inmunomoduladoras de las MSC mediante treprostinil
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US11043823B2 (en) * 2017-04-06 2021-06-22 Tesla, Inc. System and method for facilitating conditioning and testing of rechargeable battery cells
US10391156B2 (en) * 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
US20200080107A1 (en) 2018-09-07 2020-03-12 Crispr Therapeutics Ag Universal donor cells
JP2022547053A (ja) 2019-09-05 2022-11-10 クリスパー セラピューティクス アクチェンゲゼルシャフト ユニバーサルドナー細胞
CA3150235A1 (en) 2019-09-05 2021-03-11 Alireza Rezania UNIVERSAL DONOR CELLS
WO2022144856A1 (en) 2020-12-31 2022-07-07 Crispr Therapeutics Ag Universal donor cells

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1355961A (en) * 1970-02-27 1974-06-12 Wellcome Found Preparation of immunosuppressive antilymphocytic serum
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4167945A (en) * 1977-01-31 1979-09-18 Gottlieb Sheldon K Method for enhancing the healing of grafted tissue
DD145755A1 (de) * 1979-08-27 1981-01-07 Dittrich Christa Isolierungsverfahren fuer spezifische hla-antikoerper
US4399123A (en) * 1980-04-01 1983-08-16 Oliver Roy F Fibrous tissue dressing or implant
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
US5284931A (en) * 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
ATE114972T1 (de) * 1987-11-02 1994-12-15 Baylor College Medicine Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen.
FR2629347B1 (fr) * 1988-04-01 1991-06-14 Merieux Inst Procede de preparation d'un serum antilymphocytaire par immunisation d'animaux a l'aide d'un clone de lymphoblaste t humain, et serum antilymphocytaire ainsi obtenu
WO1990003400A1 (en) 1988-09-28 1990-04-05 Dana-Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US5135915A (en) 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
WO1991006105A1 (en) * 1989-10-20 1991-05-02 Australian Nuclear Science & Technology Organisation Vibratory calciners

Also Published As

Publication number Publication date
EP1484063A2 (en) 2004-12-08
JPH06503810A (ja) 1994-04-28
CA2090009A1 (en) 1992-03-01
EP0550482A4 (en) 1994-05-18
FI104732B (fi) 2000-03-31
EP1484063A3 (en) 2005-03-16
WO1992004033A1 (en) 1992-03-19
FI930886A0 (fi) 1993-02-26
JP2002104998A (ja) 2002-04-10
CA2090009C (en) 2002-07-16
EP0550482A1 (en) 1993-07-14
US5783216A (en) 1998-07-21
US6844011B1 (en) 2005-01-18
US5283058A (en) 1994-02-01
AU656150B2 (en) 1995-01-27
AU8510491A (en) 1992-03-30

Similar Documents

Publication Publication Date Title
FI930886A0 (fi) Foerfarande foer hindrande av avstoetning av transplanterad vaevnad
FI932336A0 (fi) Inhibering av celladhesionprotein-kolhydratvaexelverkan
FI930848A0 (fi) Foerfarande foer separering av ilmenit
FI931357A (fi) Framstaellning av polyhydroxifettsyraamider i naervaro av loesningsmedel
FI923931A (fi) Anordning foer granskning av insidan av en foergrenad roerlinje
FI930165A (fi) Framstaellning av synnerligen aktiva tvaettmedelspartiklar
FI931355A0 (fi) Fasoeverfoeringsmedierat foerfarande foer framstaellning av glukamidtvaettmedel
FI931356A0 (fi) Foerbaettrat katalytiskt foerfarande foer framstaellning av glukamidtvaettmedel
FI925805A (fi) Framstaellning av kompositmaterial
FI925609A0 (fi) Foerfarande foer framstaellning av sykliska sulfater
FI931879A0 (fi) Framstaellning av en peroxosyra
FI923779A (fi) Foerbaettringar i tillverkningen av nylongarn
FI931534A (fi) Foerfarande foer foerbaettring av aktiveringen av hydrauliskt masugns slagg foer framstaellning av byggnadsmaterial
FI925544A0 (fi) Bensoesyraderivat foer behandling av leukotrienassocierade sjukdomar
FI930034A0 (fi) Foerfarande foer framstaellning av avlaongt foeremaol
FI925546A0 (fi) Amidkopplade pyridylbensoesyraderivat foer behandling av leukotrien-associerade sjukdomar
FI930013A (fi) Hormonderivat av bakre hypofysloben
FI930123A (fi) Foerfarande foer anvaendning av oxiderade lipoproteiner i virusartade infektioner
FI932901A0 (fi) Foerfarande foer framstaellning av alkalimonofluorfosfat
FI932198A0 (fi) Anordning foer skydd av kondensorroer
FI923795A (fi) Kretselement foer aostadkommande av en spaerrspaenning foer kopplinsdioder
FI924154A (fi) Foerfarande foer framstaellning av penem-estrar
FI88315C (fi) Foerfarande foer blekning av cellulosamassa
FI924601A (fi) Foerbaettrat iontoforetiskt administrationssaett av laekemedel
FI931931A0 (fi) Foerfarande foer framstaellning av syntetisk wollastonit

Legal Events

Date Code Title Description
MA Patent expired